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Introduction
The sphenopalatine ganglion (SPG) resides within the
pterygopalatine fossa in close proximity to the sphenopala-
tine foramen and has been implicated in orofacial pain
conditions including migraine. Blocking the SPG using
local anesthetics may relieve pain associated with chronic
migraine.
Aim
The purpose of this study was to evaluate safety and effi-
cacy following treatment with repetitive SPG blocks using
0.5% bupivacaine vs. saline.
Methods
This was an IRB approved, 2 center, randomized, double-
blind, placebo controlled study with 41 consented adult
subjects, meeting ICHD-II definition of chronic migraine.
Subjects were randomized 2:1 following a 28 day baseline
period and received either 0.3 mL of 0.5% bupivacaine
(group A) or saline (group B) delivered to the mucosal
surface of the SPG though each nares with the Tx360®
device. The procedure was repeated twice weekly for 6
weeks with follow-up visits 1 and 6 months post
treatment.
Results
There was a 6-day reduction in headache days for group A
(p=.001) vs. a 2-day reduction for group B at 6 months
(p=.09). HIT-6 scores were lower at 6 months vs. baseline
for group A (p=.03) but not for Group B (p=.59). Further-
more, subjects receiving bupivacaine reported less work
interference (p=.004), mood interference (p=.02), general
activity (p=.05) relative to baseline. There were no signifi-
cant changes in these measures for the saline group.
Conclusion
These data suggest long-term benefits using repetitive
SPG blockade with bupivacaine delivered by the Tx360®
device. Benefits include a reduction of headache days and
improvement in several quality of life assessments.
Conflict of interest.
Published: 18 September 2014
doi:10.1186/1129-2377-15-S1-E6
Cite this article as: Cady et al.: EHMTI-0268. Long term efficacy of
repetitive sphenopalatine blockade with bupivacaine vs. Saline with the
tx360 device for treatment of chronic migraine. The Journal of Headache
and Pain 2014 15(Suppl 1):E6.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Clinvest, Banyan Group Inc., Springfield, USA
Cady et al. The Journal of Headache and Pain 2014, 15(Suppl 1):E6
http://www.thejournalofheadacheandpain.com/content/15/S1/E6
© 2014 Cady et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.
